Summary
60 / 100 · Bulios Score
What speaks for it
- Out of every 100 CNY of revenue, 19 CNY is left as net profit.
- Earnings per share grew by 17% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 1.8% a year over the last 3 years.
- It earns only 4.6 CNY a year on every 100 CNY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 26.1 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 2.5% a year over 5 years. Over the last 3 years it grew by 1.8% a year. Earnings per share grew by 17% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CNY of revenue goes
- Cost of sales 10 CNY
- Research and development 7.8 CNY
- Sales and administration 60 CNY
- Taxes and other 4.0 CNY
- Net profit 19 CNY
Net profit, industry median (Biotechnology) -6.9 CNY
Out of every 100 CNY of revenue, 19 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 4.7 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.25%
- Paid out of profit
- 33%
You receive ¥0.35 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail